APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer

INTRODUCTION: Tumor mutational burden (TMB) and APOBEC mutational signatures are potential prognostic markers in patients with advanced urothelial carcinoma (aUC). Their utility in predicting outcomes to specific therapies in aUC warrants additional study. METHODS: We retrospectively reviewed consec...

Descripción completa

Detalles Bibliográficos
Autores principales: Natesan, Divya, Zhang, Li, Martell, Henry J., Jindal, Tanya, Devine, Patrick, Stohr, Bradley, Espinosa-Mendez, Carlos, Grenert, James, Van Ziffle, Jessica, Joseph, Nancy, Umetsu, Sarah, Onodera, Courtney, Turski, Michelle, Chan, Emily, Desai, Arpita, Aggarwal, Rahul, Wong, Anthony, Porten, Sima, Chou, Jonathan, Friedlander, Terence, Fong, Lawrence, Small, Eric J., Sweet-Cordero, Alejandro, Koshkin, Vadim S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935010/
https://www.ncbi.nlm.nih.gov/pubmed/35321431
http://dx.doi.org/10.3389/fonc.2022.816706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935010/
https://www.ncbi.nlm.nih.gov/pubmed/35321431
http://dx.doi.org/10.3389/fonc.2022.816706

Ejemplares similares